Book a consult

Body Sculpting for Men — Southern California

COOLSCULPTING® FOR MEN

non-surgical fat reduction, done the measured way

The fat that survived the diet and the gym has a real, non-surgical answer. CoolSculpting® treatments use controlled cooling to reduce stubborn subcutaneous fat in a treated area — performed at Dr. Vigor® clinics, under physician supervision, with the science, the series, and the risks explained before you decide. Little to no downtime. Individual results vary.

Call 949-570-0800 Book a consult
  • Non-surgical
  • No anesthesia
  • Little to no downtime

CoolSculpting® is not a weight-loss treatment. Individual results vary. Results build over a recommended series. Candidacy is determined at a medical consultation.

The results and experiences featured on this site are examples, not promises. Individual results and patient experience vary. A medical consultation is required before any treatment.

How It Works

Fat cells freeze before anything else does

CoolSculpting® fat reduction works because fat cells are more sensitive to cold than the skin, nerves, and muscle around them. An applicator cools a pinchable area of fat to a controlled temperature, the cold damages the fat cells, and over the following weeks your immune system clears them out — usually within two to three months.[1] The category term is cryolipolysis. The skin over the area is spared, and the fat that's cleared leaves the body through normal metabolic pathways rather than moving somewhere else.[2]

How much? Published reviews report an average reduction in the fat layer of a treated area in the range of roughly 15–28% by caliper and 10–26% by ultrasound after treatment, with a pooled figure near 20% versus an untreated control site — the number you may have seen quoted as 20–25% per treatment cycle.[3][4] That's a change in the thickness of one area, not a change on the scale.[5] Individual results vary, and the range is wide for a reason: it depends on the area, on the man, and on how it's measured.

What It Treats

The spots men point to

The CoolSculpting® system is FDA-cleared for cold-assisted lipolysis — reducing the appearance of visible fat bulges — of the abdomen, the flanks, the thighs, the upper arms, the back and bra-line fat, and the fold beneath the buttocks in individuals with a BMI of 30 or less, and of the area under the chin and along the jawline, which carries its own BMI condition.[6] For men, the questions are almost always about three areas: the lower belly, the flanks, and the jawline. Clearance is specific to those listed areas, and safety and effectiveness elsewhere have not been established.

It is not a weight-loss treatment. Non-surgical body contouring changes the shape of an area — it does not treat obesity, does not produce weight loss, and does not deliver the health benefits that losing weight does.[5] If your real goal is losing a significant amount of weight, our GLP-1 weight-loss program is the honest first door, and fat reduction can follow once your weight has settled. Both doors are open, and your clinician will tell you which comes first.

A note on the phrase FDA-cleared, because it gets misused: clearance means the agency reviewed the device for those specific uses and found it substantially equivalent to a device already on the market. It is not FDA approval, and it is not an endorsement of any device, clinic, or result.[7]

See the GLP-1 weight-loss program

The Session

Cold, then numb, then back to your day

A CoolSculpting® treatment happens in a private room at a Dr. Vigor® clinic, with no anesthesia and nothing to recover from surgically. A gel pad goes over the area to protect the skin, and the applicator is positioned on the bulge — some applicators draw the tissue in with vacuum, others sit flat against it. As the cooling starts you'll feel intense cold, along with pulling or tugging where vacuum is used. After several minutes the area goes numb and most men settle in — reading, working, answering email — for the rest of the cycle.

When the applicator comes off, the treated tissue is firm and cold, and the treated area is massaged briefly to help the process along. That massage can be uncomfortable. Then you're done: most men go straight back to work or the rest of their day, with little to no downtime. A single cycle cools one area for up to about an hour,[8] and the length of your visit depends on the applicator and the number of areas in your plan — set with you at the consult.

Afterward, expect some redness, tenderness, and a numb or tingling feeling in the area. Reduced sensation is the most common lingering effect — in one small early study it had returned in every subject within a few weeks on average, and across the literature a small minority report it lasting longer than a month.[9]

The Timeline

Results arrive on the body's schedule, not the calendar's

The change is gradual by design. The cooled fat cells are cleared over weeks — the body usually finishes the job within two to three months, and one early study measured change at two months and more at six.[10] Most men notice the first difference in how clothes fit before they see it in the mirror.

Results build over a series. One treatment cycle reduces a portion of the fat in the area, and published measurements keep changing for months afterward[11] — which is why your clinician recommends the series after seeing the first result rather than selling rounds up front. FDA's own consumer guidance says the same thing: ask your provider how many treatments will be needed.[12] How many rounds, and how far apart, is your clinician's recommendation, sized to your goal and reviewed with you after the first results are in. You decide. Nobody here sells rounds by the bundle.

Once the treated fat cells are gone, they're gone — and a published five-year follow-up of two treated men showed the difference holding despite normal weight fluctuation, a small series that is consistent with how fat-cell numbers behave in adults.[13] What no fat-reduction treatment does is stop the fat cells that remain from growing if your weight goes up, and the body does slowly make new fat cells over a lifetime. Durable, yes. Weight-gain-proof, no. Individual results vary.

The Evidence

What the research says — the encouraging part first

Cryolipolysis has a substantial published literature, and the picture is a good one for the right candidate. Independent systematic reviews report measurable reductions in the fat layer of treated areas, with complications uncommon and mostly self-resolving.[14] Satisfaction is high: a 2025 meta-analysis of 30 studies pooled a satisfaction rate of about 80%, and an earlier review reported improvement in 86% of patients with 73% satisfied.[15] Individual results vary.

Honest medicine adds the qualifiers. The reduction numbers span a wide range depending on the area treated and how the change is measured, and the reviews themselves call for more standardized measurement.[16] Several of the earlier primary studies were manufacturer-affiliated, which is why this page leans on the independent reviews and meta-analyses for its numbers, and why we don't quote a single percentage as your result. What your area will do is a question we answer by measuring your own series — not with a promise.

Dr. Vigor Editorial Team

Safety & Side Effects

The full list, including the one that's easy to leave out

Most of what happens after a CoolSculpting® treatment is expected and temporary. The common effects are numbness or altered sensation, redness, swelling, bruising, tenderness, tingling, and aching in the treated area — they show up in a large share of patients and generally resolve over days to weeks.[17] Serious effects are rare. For scale, a 2025 chart review of more than 18,000 treatment cycles at one clinic group recorded any adverse event in about 2% of cycles — a clinic-record figure that captures what patients reported back, not a measure of the temporary effects above.[18]

The rare effects deserve names. They include severe or persistent pain, longer-lasting altered sensation, skin discoloration, freeze injury to the skin, a new or worsened hernia, and — the one we make sure every man hears — paradoxical adipose hyperplasia.[18] For treatments under the chin and along the jawline, the manufacturer's current labeling also lists temporary tongue or lower-lip weakness, dry mouth, and a feeling of fullness in the throat.

Paradoxical adipose hyperplasia (PAH) is a firm enlargement of the treated fat that appears two to five months after treatment instead of the expected reduction. It does not go away on its own and may require surgery to correct.[19] How often? The manufacturer's current labeling estimates about 1 in 3,000 treatments. Independent research puts it higher: a 2025 systematic review and meta-analysis pooled 28 studies and 13,078 patients and estimated about 0.22%, roughly 1 in 455 — graded low-certainty evidence, with no statistically significant difference between men and women, and an incidence the authors concluded appears higher than manufacturer reports.[20] Earlier reports described a predilection for men, and suggested that men with firm, fibrous abdominal fat or fat that sits behind the abdominal wall deserve extra care in selection.[21] Other published estimates land on both sides of the labeling figure, and the reviews note that PAH is likely under-recognized and under-reported.[22]

We tell you this because informed men make good decisions. PAH is uncommon, and it is why our screening looks hard at the type of fat in the area and not just its size — and why a prior episode of PAH rules a man out here, full stop.

Who Should Not

Our screening standard is stricter than the label

Some men should not have fat freezing at all, and we say so at the consult rather than after. Cold-sensitivity disorders come first: Raynaud's disease, pernio or chilblains, cold urticaria, cryoglobulinemia, paroxysmal cold hemoglobinuria, and cold agglutinin disease each rule it out, as does poor circulation in the area to be treated.[23] So does a hernia at or near the treatment site — the vacuum and cold can worsen one[24] — along with pregnancy, active cancer, and a prior episode of paradoxical adipose hyperplasia. Where the device labeling files some of these as cautions, we count them as hard stops. That's our standard, and it's on purpose.

Tell your clinician about everything else the device labeling flags as a caution, too: nerve pain or reduced sensation in the area, recent surgery or scar tissue there, a bleeding disorder or blood thinners, an active skin condition or open wound at the site, a known sensitivity to the gel pad's ingredients, chronic pain, or an implanted device. None of these is automatically disqualifying — each one changes what your clinician recommends, and that conversation happens before anything is scheduled.

Candidacy

The right candidate has a pinch, not a project

The procedure is designed for a discrete, pinchable pocket of subcutaneous fat — the kind you can hold between your fingers — and it doesn't move the scale,[25] which is why it suits a man who is near a weight he can maintain. If that's you, this is worth a conversation. If your weight is still moving, or the goal is your whole midsection rather than a spot on it, the honest path usually starts with our GLP-1 weight-loss program, with fat reduction as the finishing tool afterward. Either way, both doors are open and the consult is the same.

Cryolipolysis devices are prescription-use only, and every treatment here follows a candidacy decision by a licensed clinician.[26] The clinical team that performs your treatments does so at a Dr. Vigor® clinic, under physician supervision, as part of the plan set at your consult.

See both body-sculpting tracks

Reveal, Then Define

Less fat over the muscle. Then more muscle under the skin.

Fat reduction reveals what's underneath. For a lot of men, the next question is what's underneath — and the answer is Dr. Flex® magnetic muscle stimulation, which uses focused magnetic fields to trigger deep, involuntary contractions that strengthen, tone, and firm the muscle beneath the treated area.[27] Your clinician may recommend the two in sequence: reduce first, then define. That's a plan built around your goal at the consult, not a bundle.

Dr. Flex® sessions require medical screening — some conditions, including implanted electronic devices, rule treatment out. Not a weight-loss treatment and not a substitute for exercise. Individual results vary.

What Dr. Flex® muscle building is

FAQ

Questions, answered

Am I a good candidate for CoolSculpting® fat reduction?

If you have a pinchable pocket of fat that diet and training haven't moved, and you're near a weight you can hold, there's a good chance — and a licensed clinician makes that call at your consult after looking at the area and your history. CoolSculpting® treatments are not for men with cold-sensitivity disorders,[23] a hernia at the site, active cancer, or a prior episode of paradoxical adipose hyperplasia, and they are not a weight-loss treatment.

Is CoolSculpting® fat reduction safe?

For the right candidate, the published safety profile is well described: the common effects — numbness, redness, swelling, bruising, tenderness — are temporary, and serious effects are rare — for scale, one large chart review recorded any adverse event, mostly the temporary kind, in about 2% of treatment cycles.[18] The rare effects, including paradoxical adipose hyperplasia, are named and explained in the safety section above, because knowing them is part of deciding well.

Does it hurt?

Most men describe it as intense cold and pulling for the first several minutes, then numbness for the rest of the cycle — uncomfortable at the start, and most men tolerate it well. The brief massage afterward can sting. There's no anesthesia because none is needed. Patient experiences vary, and your clinician will walk you through it before your first CoolSculpting® treatment.

How long is a session?

A single treatment cycle cools one area for up to about an hour,[8] and the length of your visit depends on the applicator and the number of areas in your plan. Your clinician sets the specifics at the consult. Most men go straight back to their day after a CoolSculpting® treatment, with little to no downtime.

How many treatments will I need?

Usually more than one. Each treatment cycle reduces a portion of the fat in the area, published measurements keep changing for months afterward,[11] and FDA's consumer guidance says to ask your provider how many treatments will be needed[12] — which is why results build over a recommended series. Your clinician recommends the series that fits your goal and reviews it with you once the first results are in — you decide, and nobody here sells rounds by the bundle.

When will I see results, and where does the fat go?

Gradually. The cooled fat cells are cleared by your body over the following weeks — usually within two to three months, with studies measuring change at two months and more at six.[10] The fat leaves through the body's normal metabolic pathways rather than moving to another area.[2] Individual results vary.

Will the fat come back?

The treated fat cells are gone, and a published five-year follow-up of two treated men showed the difference holding despite normal weight fluctuation — a small series, consistent with how fat-cell numbers behave in adults.[13] The fat cells that remain can still grow with weight gain, and the body slowly makes new ones over time — so CoolSculpting® results are durable, not weight-gain-proof. The men who keep them are the men who keep their habits. Individual results vary.

Is there downtime?

Little to no downtime for most men. A CoolSculpting® treatment involves no surgery and no anesthesia, and most men return to work the same day. Expect temporary numbness, redness, or tenderness in the area for days to a few weeks.[17]

What does CoolSculpting® fat reduction cost?

Pricing depends on the areas and the series your clinician recommends. You'll know your full cost before you start. Call 949-570-0800 and ask — nobody will make you book to find out.

Citations & References

The research behind this page

Every clinical and regulatory statement on this page resolves to a U.S. government (.gov) record — a National Library of Medicine listing (PubMed or PubMed Central) for peer-reviewed research, an FDA regulatory record, or a federal health authority's own page. Each reference was resolved and checked against that record during the build. Indexing is not endorsement: FDA clearance is not FDA approval, and no citation here implies that any government agency vouches for this clinic, these devices, or any result.

  1. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. Manstein D, Laubach H, Watanabe K, Farinelli W, Zurakowski D, Anderson RR. Selective cryolysis: a novel method of non-invasive fat removal. Lasers Surg Med. 2008;40(9):595–604. PMID: 18951424. Avram MM, Harry RS. Cryolipolysis for subcutaneous fat layer reduction. Lasers Surg Med. 2009;41(10):703–708. PMID: 20014262. FDA: fat cells are uniquely sensitive to cold, so controlled cooling targets them while sparing skin, and the released fat is cleared by the immune system usually within two to three months. Manstein 2008: the founding preclinical study — cold-induced, selective loss of subcutaneous fat occurring gradually over the study period without skin injury. Avram 2009: gradual thinning of the fat layer over two to four months with only minor, temporary effects.
  2. Zelickson B, Egbert BM, Preciado J, et al. Cryolipolysis for noninvasive fat cell destruction: initial results from a pig model. Dermatol Surg. 2009;35(10):1462–1470. PMID: 19614940. Zelickson 2009: in the pig model, cold-induced apoptosis of fat cells and an inflammatory response preceded the reduction in the fat layer, with normal cholesterol and triglyceride levels over three months.
  3. Ingargiola MJ, Motakef S, Chung MT, Vasconez HC, Sasaki GH. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015;135(6):1581–1590. PMID: 26017594. PMC4444424. Derrick CD, Shridharani SM, Broyles JM. The safety and efficacy of cryolipolysis: a systematic review of available literature. Aesthet Surg J. 2015;35(7):830–836. PMID: 26038367. Coleman SR, Sachdeva K, Egbert BM, Preciado J, Allison J. Clinical efficacy of noninvasive cryolipolysis and its effects on peripheral nerves. Aesthetic Plast Surg. 2009;33(4):482–488. PMID: 19296153. Ingargiola 2015 systematic review (19 studies): average reduction of 14.67–28.5% by caliper and 10.3–25.5% by ultrasound. Derrick 2015 systematic review (1,445 patients): mean 19.55% reduction versus an untreated control site at a mean 3.83 months. Coleman 2009 (10 subjects, manufacturer-affiliated): 20.4% at two months and 25.5% at six months.
  4. Krueger N, Mai SV, Luebberding S, Sadick NS. Cryolipolysis for noninvasive body contouring: clinical efficacy and patient satisfaction. Clin Cosmet Investig Dermatol. 2014;7:201–205. PMID: 25061326. PMC4079633. Nelson AA, Wasserman D, Avram MM. Cryolipolysis for reduction of excess adipose tissue. Semin Cutan Med Surg. 2009;28(4):244–249. PMID: 20123423. Krueger 2014 review: fat reduction of up to 25% after a single treatment reported, improvement seen in 86% of patients, and 73% patient satisfaction, with temporary side effects. Nelson 2009 review: a gradual decrease in fat thickness over about three months after a single treatment.
  5. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. Hakami A, Hakami A, Alghamdi R, et al. Effectiveness of cryolipolysis in body contouring and fat reduction: a systematic review and meta-analysis. World J Plast Surg. 2025. PMID: 41607567. PMC12843028. FDA: non-invasive body contouring does not treat obesity or improve your health and will not result in weight loss. Hakami 2025 meta-analysis: fat thickness reduced, overall weight not significantly affected.
  6. U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Premarket Notification K233732 — CoolSculpting® system, current-generation clearance. Decision: substantially equivalent, September 12, 2024. 21 CFR 878.4340, product code OOK. FDA 510(k) K233732 (September 12, 2024): cleared for cold-assisted lipolysis of the upper arm, bra fat, back fat, banana roll, thigh, abdomen, and flank in individuals with a BMI of 30 or less, and of the submental and submandibular areas, to affect the appearance of visible fat bulges.
  7. U.S. Food and Drug Administration. Is It Really ‘FDA Approved’? Content current as of May 4, 2026. FDA: Class II devices are marketed under 510(k) clearance on a showing of substantial equivalence to a legally marketed predicate — distinct from premarket approval — and FDA's name may not be used to suggest endorsement of any private organization or product.
  8. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: the targeted, pinchable fat is drawn into an applicator and cooled for up to one hour.
  9. Coleman SR, Sachdeva K, Egbert BM, Preciado J, Allison J. Clinical efficacy of noninvasive cryolipolysis and its effects on peripheral nerves. Aesthetic Plast Surg. 2009;33(4):482–488. PMID: 19296153. Derrick CD, Shridharani SM, Broyles JM. The safety and efficacy of cryolipolysis: a systematic review of available literature. Aesthet Surg J. 2015;35(7):830–836. PMID: 26038367. Coleman 2009: transient reduction in sensation in six of nine subjects, with all sensation returning by a mean of 3.6 weeks and no lasting nerve changes on biopsy. Derrick 2015: the most common complication was diminished sensation lasting more than four weeks, in a small minority.
  10. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. Nelson AA, Wasserman D, Avram MM. Cryolipolysis for reduction of excess adipose tissue. Semin Cutan Med Surg. 2009;28(4):244–249. PMID: 20123423. Coleman SR, Sachdeva K, Egbert BM, Preciado J, Allison J. Clinical efficacy of noninvasive cryolipolysis and its effects on peripheral nerves. Aesthetic Plast Surg. 2009;33(4):482–488. PMID: 19296153. FDA: released fat is cleared usually within two to three months. Nelson 2009: fat thickness decreases gradually over three months. Coleman 2009: reduction measured at two months and greater at six months.
  11. Derrick CD, Shridharani SM, Broyles JM. The safety and efficacy of cryolipolysis: a systematic review of available literature. Aesthet Surg J. 2015;35(7):830–836. PMID: 26038367. Coleman SR, Sachdeva K, Egbert BM, Preciado J, Allison J. Clinical efficacy of noninvasive cryolipolysis and its effects on peripheral nerves. Aesthetic Plast Surg. 2009;33(4):482–488. PMID: 19296153. Derrick 2015: pooled results measured at a mean 3.83 months after treatment. Coleman 2009: reduction continued to increase between the two-month and six-month measurements — change keeps building for months after a treatment.
  12. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: ask your health care provider how many treatments will be needed.
  13. Bernstein EF. Longitudinal evaluation of cryolipolysis efficacy: two case studies. J Cosmet Dermatol. 2013;12(2):149–152. PMID: 23725309. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453(7196):783–787. PMID: 18454136. Bernstein 2013: two men treated on one flank, photographed at two and five years — durable results despite natural fluctuations in body weight. Spalding 2008: adult fat-cell number is set early and turns over slowly (a small fraction renewed each year), so fat mass changes largely through the size of existing cells.
  14. Ingargiola MJ, Motakef S, Chung MT, Vasconez HC, Sasaki GH. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015;135(6):1581–1590. PMID: 26017594. PMC4444424. Derrick CD, Shridharani SM, Broyles JM. The safety and efficacy of cryolipolysis: a systematic review of available literature. Aesthet Surg J. 2015;35(7):830–836. PMID: 26038367. Ingargiola 2015 (19 studies): average reductions of 14.67–28.5% by caliper and 10.3–25.5% by ultrasound with only mild, short-term side effects. Derrick 2015 (1,445 patients): mean 19.55% reduction versus an untreated control site, complications in 0.82% and resolving without intervention.
  15. Ravindran R, Pizzol D, Rahmati M, et al. Cryolipolysis and associated health outcomes, adverse events, and satisfaction: a systematic review and meta-analysis. Obes Rev. 2025. doi:10.1111/obr.13925. PMID: 40211915. PMC12246886. Krueger N, Mai SV, Luebberding S, Sadick NS. Cryolipolysis for noninvasive body contouring: clinical efficacy and patient satisfaction. Clin Cosmet Investig Dermatol. 2014;7:201–205. PMID: 25061326. PMC4079633. Ravindran 2025 meta-analysis (30 studies, 3,158 participants): pooled satisfaction rate 80.4%. Krueger 2014 review: 73% patient satisfaction and improvement in 86% of patients.
  16. Ingargiola MJ, Motakef S, Chung MT, Vasconez HC, Sasaki GH. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015;135(6):1581–1590. PMID: 26017594. PMC4444424. Derrick CD, Shridharani SM, Broyles JM. The safety and efficacy of cryolipolysis: a systematic review of available literature. Aesthet Surg J. 2015;35(7):830–836. PMID: 26038367. The reported reduction ranges across studies (roughly 10–28% depending on the measure and the area) and the reviews' calls for standardized measurement — results vary by area, by measurement method, and by patient.
  17. Ravindran R, Pizzol D, Rahmati M, et al. Cryolipolysis and associated health outcomes, adverse events, and satisfaction: a systematic review and meta-analysis. Obes Rev. 2025. doi:10.1111/obr.13925. PMID: 40211915. PMC12246886. Hedayati B, Juhász M, Chu S, Mesinkovska NA. Adverse events associated with cryolipolysis: a systematic review of the literature. Dermatol Surg. 2020;46(Suppl 1):S8–S13. doi:10.1097/DSS.0000000000002524. PMID: 32976167. Ravindran 2025: the most frequently reported effects were numbness (49.5%), redness (44.5%), swelling (30.5%), and pain (28.8%). 2020 systematic review of adverse events (53 articles): the most common were treatment-site redness, numbness or altered sensation, bruising, and swelling, with most minimal and resolving quickly.
  18. Hedayati B, Juhász M, Chu S, Mesinkovska NA. Adverse events associated with cryolipolysis: a systematic review of the literature. Dermatol Surg. 2020;46(Suppl 1):S8–S13. doi:10.1097/DSS.0000000000002524. PMID: 32976167. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. Friedmann DP, Kommera J, Durga P, Shashidhar A, Verma KK. Evaluating real-world use and adverse events from 3262 patients treated with 18,203 cycles of cryolipolysis for localized fat reduction: a multi-location practice retrospective chart review. Aesthet Surg J. 2025. doi:10.1093/asj/sjaf007. PMID: 39829238. Hedayati 2020 systematic review: more serious complications include severe or persistent pain, dysesthesia, skin hyperpigmentation, motor neuropathy, and paradoxical adipose hyperplasia — serious, sometimes irreversible, and to be counseled before treatment. FDA: less common risks include numbness persisting for weeks and freeze burns, hernias have been reported, and nerve effects can follow treatment under the jawline. Friedmann 2025 multi-location chart review (3,262 patients, 18,203 cycles): 180 adverse events in 87 patients — 2.05% of cycles — including two patients with paradoxical adipose hyperplasia.
  19. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: paradoxical adipose hyperplasia is fatty tissue growing instead of shrinking in the treated area, typically two to five months after the procedure; it does not go away on its own and may require surgery to remove the visible bulge.
  20. Mah AE, Razeghi P, Li C, et al. Incidence of paradoxical adipose hyperplasia after cryolipolysis: a systematic review and meta-analysis. Aesthet Surg J Open Forum. 2025;7:ojaf142. doi:10.1093/asjof/ojaf142. PMID: 41322038. PMC12662051. Mah 2025 systematic review and meta-analysis (28 studies, 13,078 patients): pooled incidence 0.22% (95% CI 0.10–0.47), about 1 in 455 patients — graded low-certainty evidence, with sex-based differences not statistically significant, and an overall incidence that appears higher than manufacturer reports.
  21. Keaney TC, Naga LI. Men at risk for paradoxical adipose hyperplasia after cryolipolysis. J Cosmet Dermatol. 2016;15(4):575–577. doi:10.1111/jocd.12256. PMID: 27432593. Jalian HR, Avram MM, Garibyan L, Mihm MC, Anderson RR. Paradoxical adipose hyperplasia after cryolipolysis. JAMA Dermatol. 2014;150(3):317–319. PMID: 24382640. Keaney 2016: reports suggest PAH may be more common than expected with a predilection for men, and careful selection avoiding men with visceral abdominal fat and firm, non-distensible, fibrous fat may reduce risk. Jalian 2014 (first published series): the phenomenon seems more common in male patients, with no evidence of spontaneous resolution.
  22. Jalian HR, Avram MM, Garibyan L, Mihm MC, Anderson RR. Paradoxical adipose hyperplasia after cryolipolysis. JAMA Dermatol. 2014;150(3):317–319. PMID: 24382640. Friedmann DP, Kommera J, Durga P, Shashidhar A, Verma KK. Evaluating real-world use and adverse events from 3262 patients treated with 18,203 cycles of cryolipolysis for localized fat reduction: a multi-location practice retrospective chart review. Aesthet Surg J. 2025. doi:10.1093/asj/sjaf007. PMID: 39829238. Mah AE, Razeghi P, Li C, et al. Incidence of paradoxical adipose hyperplasia after cryolipolysis: a systematic review and meta-analysis. Aesthet Surg J Open Forum. 2025;7:ojaf142. doi:10.1093/asjof/ojaf142. PMID: 41322038. PMC12662051. The published range of incidence estimates: 0.0051% in the first report (Jalian 2014) and 0.018–0.048% per cycle in a 2025 multi-location chart review, against the 2025 pooled estimate of 0.22%. Mah 2025: emerging literature suggests PAH may be underrecognized and underreported.
  23. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: you should not have a fat-freezing procedure if you have Raynaud's disease, pernio or chilblains, cold urticaria, cryoglobulinemia, paroxysmal cold hemoglobinuria or cold agglutinin disease, or poor blood circulation in the treatment area.
  24. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: hernias have been reported in treated areas and are listed among the risks of cryolipolysis.
  25. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. Hakami A, Hakami A, Alghamdi R, et al. Effectiveness of cryolipolysis in body contouring and fat reduction: a systematic review and meta-analysis. World J Plast Surg. 2025. PMID: 41607567. PMC12843028. FDA: the procedure draws targeted, pinchable fat into an applicator and does not treat obesity or produce weight loss. Hakami 2025: local fat thickness reduced, overall weight not significantly affected — the treatment is for a spot, not for the scale.
  26. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. FDA: devices that use this technology are for prescription use only, and only devices authorized by FDA for cosmetic use should be used.
  27. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Premarket Notification K253408 — powered muscle stimulator for muscle conditioning (magnetic muscle stimulation device), 21 CFR 890.5850, product codes NGX and IPF. Decision: substantially equivalent, January 16, 2026. FDA: pulsed magnetic fields trigger repeated muscle contractions that may improve muscle tone and firmness. K253408: the cleared indications for the muscle-stimulation device class — abdominal tone and strength, and strengthening, toning, and firming of buttocks and thighs.

Getting Started

Start with a consult. FINISH STRONG®.

Getting started is simple.

  1. Step 01

    Talk

    A focused consult — virtual if you like.

  2. Step 02

    Test

    An in-person visit: vitals and bloodwork before any products or services.

  3. Step 03

    Tune

    Proven protocols do the groundwork. Your clinician makes the call — your plan, adjusted over time to your progress and how you actually feel.

Book a consult Call 949-570-0800

Individual results vary. Treatment only when clinically appropriate.

Dr. Vigor® clinics in California are 100% physician-owned. CoolSculpting® treatments are provided only after evaluation by a licensed clinician, and only when clinically appropriate. A medical consultation is required before any treatment. Treatments are performed at Dr. Vigor clinic locations by the practice's trained clinical team under physician supervision. The CoolSculpting® system is FDA-cleared for cold-assisted lipolysis of specific body areas; clearance is claimed only for the areas listed in the device's current FDA clearance and labeling, and safety and effectiveness elsewhere have not been established. FDA clearance is not FDA approval and is not an endorsement. CoolSculpting® is not a weight-loss treatment and does not treat obesity. Results build over a recommended series of treatments, are not guaranteed, and vary by individual. Not all men, and not all areas, are candidates. Treatment plans are set by the patient's own licensed clinician, who alone determines candidacy and course of treatment — protocols inform that judgment and never replace it. Dr. Vigor is a concierge clinic group and does not bill insurance. Services available in California at Dr. Vigor clinic locations. CoolSculpting® is a registered trademark of Allergan Aesthetics, an AbbVie company. Dr. Vigor is not affiliated with or endorsed by Allergan Aesthetics.

Dr. Vigor® clinics in California are 100% physician-owned. CoolSculpting® treatments are provided only after evaluation by a licensed clinician, and only when clinically appropriate. A medical consultation is required before any treatment. Treatments are performed at Dr. Vigor clinic locations by the practice's trained clinical team under physician supervision. The CoolSculpting® system is FDA-cleared for cold-assisted lipolysis of specific body areas; clearance is claimed only for the areas listed in the device's current FDA clearance and labeling, and safety and effectiveness elsewhere have not been established. FDA clearance is not FDA approval and is not an endorsement. CoolSculpting® is not a weight-loss treatment and does not treat obesity. Results build over a recommended series of treatments, are not guaranteed, and vary by individual. Not all men, and not all areas, are candidates. Treatment plans are set by the patient's own licensed clinician, who alone determines candidacy and course of treatment — protocols inform that judgment and never replace it. Dr. Vigor is a concierge clinic group and does not bill insurance. Services available in California at Dr. Vigor clinic locations. CoolSculpting® is a registered trademark of Allergan Aesthetics, an AbbVie company. Dr. Vigor is not affiliated with or endorsed by Allergan Aesthetics.

BookCall